Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aspire Biopharma Holdings, Inc. (ASBP : NSDQ)

• Company Description    Aspire Biopharma Inc. is a privately held, early-stage biopharmaceutical technology company. It engaged in the business of developing and marketing a disruptive technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals and supplements. Aspire Biopharma Inc., formerly known as PowerUp Acquisition Corp., is based in NEW YORK. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $7.26 Daily Weekly Monthly 20 Day Moving Average: 70,607 shares Shares Outstanding: 1.30 (millions) Market Capitalization: $9.40 (millions) Beta: 0.15 52 Week High: $1,050.36 52 Week Low: $3.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.47% 11.64% 12 Week 9.24% 6.25% Year To Date -95.42% -95.79%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 23150 Fashion Dr. Suite 232 - Estero,FL 33928 USA ph: 908-987-3002 fax: - kevin@tradigitalir.com http://www.aspirebiolabs.com

• General Corporate Information    Officers Kraig T. Higginson - Chief Executive Officer and Chairman Ernest J Scheidemann - Chief Financial Officer Howard Doss - Director Edward J. Kimball - Director Philip Balatsos - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 738920305 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 1.30 Most Recent Split Date: 5.00 (0.03:1) Beta: 0.15 Market Capitalization: $9.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.31 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 95.92% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 557.12% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - - 03/31/26 - -398.04 12/31/25 - -1,468.13 Current Ratio 06/30/26 - - 03/31/26 - 2.26 12/31/25 - 0.17 Quick Ratio 06/30/26 - - 03/31/26 - 2.14 12/31/25 - 0.14 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - -34,333.49 12/31/25 - -394,727.50 Book Value 06/30/26 - - 03/31/26 - 23.10 12/31/25 - -54.19 Inventory Turnover 06/30/26 - - 03/31/26 - 0.18 12/31/25 - 0.09 Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - -

Powered by Zacks Investment Research ©